Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Bullous Pemphigoid
Interventions: efgartigimod PH20 SC, placebo, Prednisone; Biological · Other · Drug
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more

Conditions: Migraine Headache
Interventions: Erenumab 70 mg, Erenumab 140 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 32
States / cities: Cerritos, California • Colton, California • Los Angeles, California + 28 more

Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg; Drug · Biological · Dietary Supplement
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Caloric Restriction, Exercise, Sleep
Interventions: Testosterone Undecanoate, Sesame Oil; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Parkinson Disease
Interventions: Onabotulinumtoxin A Injection, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: APG777, Placebo; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: La Jolla, California • Long Beach, California • San Jose, California + 6 more

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Crohn Colitis
Interventions: Remestemcel-L, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Safety Issues
Interventions: VIB9600, Placebos; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more

Conditions: Head and Neck Cancer
Interventions: PepCan, Placebo; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Knee Osteoarthritis
Interventions: Placebo, SM04690; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Canoga Park, California • Carmichael, California + 9 more

Conditions: Scar
Interventions: Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio • Westlake, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 94
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more

Conditions: Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions: HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions: 25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Peanut Allergy, Food Allergy
Interventions: Omalizumab, placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 7 Years to 25 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 4
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Genital Herpes Simplex Type 2
Interventions: BNT163, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Rheumatoid Arthritis RA
Interventions: Efavaleukin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more

Conditions: Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: recombinant human growth hormone (rhGH), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

A Phase1 Study of VIB9600

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls